Loading stock data…
Harmony Biosciences Holdings (HRMY)
$42.07-0.18 (-0.43%)
Market ClosedLast close Sep 8
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Harmony Biosciences Holdings, Inc. in the Healthcare sector is trading at $42.07 with a market capitalization of $2.0B. Wall Street consensus targets $47.36 (11 analysts), implying a +12.6% move over the next 12 months. The stock is currently near its 52-week high of $43.49, remaining 22.9% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +12.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $215.39M↓ | $243.78M↑ | $239.46M↑ | $200.49M↑ | $184.73M |
| Gross Profit | $170.88M↓ | $175.23M↓ | $179.81M↑ | $162.34M↑ | $152.74M |
| Operating Income | $37.29M↓ | $38.56M↓ | $65.49M↑ | $48.18M↓ | $56.24M |
| Net Income | $32.49M↑ | $22.49M↓ | $50.87M↑ | $39.78M↓ | $45.56M |
Peer Comparison
JNJUNHPFE
Fundamentals
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule wi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.98B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
16.00%
Volume
Today's trading volume
1.76M
Recent News
Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?
Harmony Biosciences (HRMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intuit downgraded, SolarEdge upgraded: Wall Street's top analyst calls
Intuit downgraded, SolarEdge upgraded: Wall Street's top analyst calls
Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline
Harmony Biosciences (NASDAQ:HRMY) highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy and pitolisant lifecycle-management programs during Piper Sandler’s virtual CNS Symposium. Peter Anastasiou, the company’s chief o
Harmony Biosciences (HRMY) Q2 2026 Earnings Call Transcript
WAKIX revenue surged 30% to $261.3 million, confirming $1 billion annual guidance.